Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 7/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587158 | 1.00 | LPAR3 (0.41) | LPAR3LPAR2S1PR1S1PR3S1PR4 | |
| SCHEMBL4587154 | 1.00 | LPAR3 (0.41) | LPAR3LPAR2S1PR1S1PR3S1PR4 | |
| SCHEMBL4586270 | 0.95 | GABBR2 (0.39) | LPAR3LPAR2S1PR1S1PR3S1PR4 | |
| SCHEMBL4586126 | 0.95 | GABBR2 (0.39) | LPAR3LPAR2S1PR1S1PR3S1PR4 | |
| SCHEMBL4586130 | 0.95 | GABBR2 (0.39) | LPAR3LPAR2S1PR1S1PR3S1PR4 | |
| SCHEMBL4588056 | 0.88 | S1PR4 (0.34) | S1PR1S1PR3S1PR4 | |
| SCHEMBL4585664 | 0.88 | S1PR4 (0.34) | S1PR1S1PR3S1PR4 | |
| SCHEMBL4585668 | 0.88 | S1PR4 (0.34) | S1PR1S1PR3S1PR4 | |
| SCHEMBL4587058 | 0.76 | S1PR4 (0.40) | LPAR3LPAR2S1PR1S1PR3S1PR4 | |
| SCHEMBL7859641 | 0.75 | LPAR3 (0.52) | LPAR3LPAR2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458669-A4 | NEUOROLOGICALLY-ACTIVE COMPOUNDS | UNIV SYDNEY (AU) | 2008-10-29 | — | — | EP | disclosed |
| US-6962907-B2 | Neurologically-active compounds | THE UNIVERSITY OF SYDNEY (AU) | 2005-11-08 | — | — | US | disclosed |
| US-20050004083-A1 | Neurologically-active compounds | NEURO THERAPEUTICS LIMITED (AU) | 2005-01-06 | — | — | US | disclosed |
| EP-1458669-A1 | NEUOROLOGICALLY-ACTIVE COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003045897-A1 | NEOROLOGICALLY-ACTIVE COMPOUNDS | UNIVERSITY OF SYDNEY (AU) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004083-A1 | Neurologically-active compounds | GABRA2, GABRA5, GABRE | LPAR3 606/4885LPAR2 298/4885S1PR1 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.